Research on AS in management of prostate cancer: your input is important! | THE "NEW" PROSTATE CANCER INFOLINK

Research on AS in management of prostate cancer: your input is important! | THE "NEW" PROSTATE CANCER INFOLINK

prostatecancerinfolink.net

Research on AS in management of prostate cancer: your input is important!

4 minutes

A diverse group of patients, patient advocates, patient spouses/supporters, physicians, and other researchers has come together, with funding support from the Patient Centered Outcomes Research Institute (PCORI), to plan a virtual conference for the fall of 2021. At that conference, we intend to discuss and identify new and evolving opportunities for research into the most appropriate, high-need, high-impact topics affecting the use of active surveillance (AS) for the management of favorable-risk forms of prostate cancer (i.e., low-risk and “favorable” intermediate-risk disease).

Our goal is to bring together patient, clinician, and academic input and thus jointly identify critical research topics that we hope will guide future research for years to come.

Initial patient and clinician input will be invaluable for helping set the agenda for this meeting.  The first stage of gaining this input begins today, with a request for interested persons to please fill out this BRIEF survey related to topics that YOU think are important to the future use of AS in the management of prostate cancer. We are seeking such input from patients, patients’ spouses/partners and supporters/caregivers, physicians, nurses and others.

While we expect the majority of persons providing input to this project will be based in the USA, we are interested in input to this project from persons based anywhere in the world.

You are also invited to the fall conference! So, if you are interested, please provide your email address at the end of the survey and we will make sure you get relevant updates.

This project is being managed by a research team based at the University of Maryland in Baltimore. The principal investigator is M. Minhaj Siddiqui, MD (a urologic oncologist based at the University of Maryland). The following is a complete list of the members of the advisory board to the project:

  • Carolyn J. M. Best, PhD, Director of Research, American Urological Association, Linthicum, MD
  • Tony Crispino, a prostate cancer patient and President, US TOO Las Vegas Chapter, Las Vegas, NV
  • Thomas Farrington, a prostate cancer patient and President, Prostate Health Education Network (PHEN), Quincy, MA
  • Joseph C. Gallo, a prostate cancer patient, and Member of the Board of Directors, Active Surveillance Patients International (ASPI), Warrington, PA
  • Arvin George, MD, Department of Urology, University of Michigan, Ann Arbor, MI
  • Prof. C. Daniel Mullins, PhD, Director, the PATIENTS Program, University of Maryland, Baltimore, MD
  • Prof. Christian P. Pavlovich, MD, PhD, Department of Urology, Johns Hopkins Medicine, Baltimore, MD
  • Prof. David Penson, MD, MPH, MMHC, Chairman, Department of Urology, Vanderbilt University, KY
  • Peter A. Pinto, MD, Urologic Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD
  • Prof. Christopher E. Saigal, MD, MPH, Department of Urology, UCLA School of Medicine, Los Angeles, CA
  • E. Michael D. Scott, President and Executive Director, Prostate Cancer International, Virginia Beach, VA
  • Judi Wolinsky, spouse of a prostate cancer patient, Chicago, IL

Should readers have any questions about this project, please feel able to contact the project coordinator, Andrelle Mathelier, at the University of Maryland.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , |

 

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more